Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice.

摘要: Some anti-diabetic therapies can have adverse effects on bone health and increase fracture risk. In this study, we tested the skeletal of chronic administration two Glucagon-like peptide-1 receptor agonists (GLP-1RA), increasingly used for type 2 diabetes treatment, in a model osteoporosis associated loss examined expression activation GLP-1R cells. Mice were ovariectomised (OVX) to induce four weeks later they treated with Liraglutide (LIR) 0.3mg/kg/day, Exenatide (Ex-4) 10 μg/kg/day or saline weeks. injected calcein alizarin red prior euthanasia, label bone-mineralising surfaces. Tibial micro-architecture was determined by micro-CT formation resorption parameters measured histomorphometric analysis. Serum collected measure calcitonin sclerostin levels, inhibitors formation, respectively. mRNA protein evaluated bone, marrow cells using RT-PCR immunohistochemistry. Primary osteoclasts osteoblasts cultured evaluate effect GLP-1RA vitro. significantly increased trabecular mass, connectivity structure but had no cortical bone. There vivo an osteoclast number surfaces observed Ex-4. expressed cells, primary late osteocytic cell line. Both Ex-4 LIR stimulated osteoclastic differentiation vitro slightly reduced area resorbed per osteoclast. They nodule levels decreased not LIR. Thus, beneficial may imply that these are exerted directly tissue.